Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Omvoh ® ▼ (mirikizumab)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Omvoh® (mirikizumab): Pregnancies in the Ulcerative Colitis and Crohn's Disease Clinical Trials
With limited data from the use of mirikizumab in pregnant women, it is preferable to avoid use during pregnancy. Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment.
Content overview
Information from the Summary of Product Characteristics
LUCENT and VIVID Clinical Study Protocols
Pregnancies During the Mirikizumab Clinical Studies
- Pregnancies in Mirikizumab-Exposed Study Participants
- Pregnancies in Partners of Male Study Participants Exposed to Mirikizumab
Information from the Summary of Product Characteristics
For information on pregnancy, as well as on the related topics of contraception, breastfeeding and fertility, please refer to the Omvoh Summary of Product Characteristics, in particular the section on1
- 4.6 Fertility, pregnancy and lactation
In the clinical trials, several women became pregnant while using mirikizumab. Below you will find more information about these pregnancies in ulcerative colitis and Crohn's disease clinical trials.
LUCENT and VIVID Clinical Study Protocols
Per the protocol for the LUCENT and VIVID clinical trials, women of childbearing potential were required to
Pregnancies During the Mirikizumab Clinical Studies
Pregnancies in Mirikizumab-Exposed Study Participants
As of October 4, 2023, 36 women exposed to mirikizumab became pregnant during an ulcerative colitis, Crohn's disease, or psoriasis clinical study.3 For details, please see Pregnancies in Female Participants Exposed to Mirikizumab.
Outcome |
Number of Events (n) |
Crohn's disease (N=11) |
|
Normal outcomea |
4 |
Elective abortion |
1 |
Spontaneous abortion |
4 |
Unknown, lost to follow-up |
1 |
Pregnancy still ongoing |
1 |
Ulcerative colitis (N=11) |
|
Normal outcomeb |
2 |
Elective abortion |
2 |
Spontaneous abortion |
1 |
Unknown, lost to follow-up |
2 |
Pregnancy still ongoing |
3 |
Birth defectc |
1 |
Psoriasis (N=14) |
|
Normal outcome |
9 |
Elective abortion |
2 |
Spontaneous abortion |
0 |
Unknown, lost to follow-up |
3 |
All Mirikizumab (N=36) |
|
Normal outcome |
15 |
Elective abortion |
5 |
Spontaneous abortion |
5 |
Unknown, lost to follow-up |
6 |
Pregnancy still ongoing |
4 |
Birth defectc |
1 |
Abbreviations: n = number of events; N = number of participants in the specified category.
aOne of the 4 cases was a low-weight birth with a healthy baby.
bOne of the 2 cases was a preterm birth with a healthy baby.
cThe birth defect was Treacher Collins syndrome.
Pregnancies in Partners of Male Study Participants Exposed to Mirikizumab
As of October 4, 2023, 52 partners of male participants became pregnant during the male participants' participation in a mirikizumab clinical study for ulcerative colitis, Crohn's disease, or psoriasis.3 For details, please see Pregnancies in Partners of Male Participants Exposed to Mirikizumab.
Outcome |
Number of Events (n) |
Crohn's disease (N=12) |
|
Normal outcome |
9 |
Elective abortion |
0 |
Spontaneous abortion |
0 |
Unknown, lost to follow-up |
2 |
Pregnancy still ongoing |
1 |
Ulcerative colitis (N=18) |
|
Normal outcome |
7 |
Elective abortion |
0 |
Spontaneous abortion |
6 |
Unknown, lost to follow-up |
4 |
Pregnancy still ongoing |
1 |
Psoriasis (N=22) |
|
Normal outcome |
14 |
Elective abortion |
1 |
Spontaneous abortion |
2 |
Unknown, lost to follow-up |
4 |
Birth defecta |
1 |
All Mirikizumab (N=52) |
|
Normal outcome |
30 |
Elective abortion |
1 |
Spontaneous abortion |
8 |
Unknown lost to follow-up |
10 |
Pregnancy still ongoing |
2 |
Birth defecta |
1 |
Abbreviations: n = number of events; N = number of participants in the specified category.
aThis was a preterm birth and the baby had Wolf–Hirschhorn syndrome.
Background Risk
All pregnancies have a background risk of birth defects, loss, or other adverse outcomes.3
In the US general population, in clinically recognized pregnancies the estimated background risk of
- major birth defects is 2% to 4%, and
- miscarriage is 15% to 20%.3
Among patients with inflammatory bowel disease, results from observational studies indicate that the incidence of
- congenital malformations ranges from 2.7% to 9.0%, and
- spontaneous abortions ranges from 3% to 17%.3
Among patients with Crohn's disease, results from observational studies indicate that the incidence of
- congenital malformations ranges from 1.9% to 8.6%, and
- spontaneous abortions ranges from 4.4% to 15.9%.3
Mirikizumab Pregnancy Registry Information
There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mirikizumab during pregnancy in the United States.3
Information regarding a mirikizumab pregnancy exposure registry outside the United States is not currently available.3
References
1Omvoh 300 mg concentrate for solution for infusion [summary of product characteristics] Eli Lilly Nederland B.V., The Netherlands (UK)
2D'Haens G, Dubinsky M, Kobayashi T, et al; LUCENT Study Group. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444-2455. https://doi.org/10.1056/NEJMoa2207940
3Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 26 January 2025